NeuroSense Therapeutics granted Brazilian patent for PrimeC

(Cambridge, MA) NeuroSense Therapeutics has secured Brazilian patent protection for its lead drug candidate PrimeC through October 2042. This grant follows similar approvals in the United States and Australia strengthening the company's global intellectual property estate for its multi-target neurodegenerative treatments.

PrimeC is a proprietary fixed-dose oral combination of ciprofloxacin and celecoxib featuring a synchronized extended-release formulation. This delivery method distinguishes it from simple co-administration by ensuring consistent exposure to multiple disease pathways including neuroinflammation, iron dysregulation, and RNA regulation.

The company is currently preparing for the PARAGON Phase 3 pivotal clinical trial in ALS following positive Phase 2b results and FDA clearance. PrimeC is also being developed for Alzheimer's disease and other neurodegenerative indications where multi-target approaches may address significant unmet medical needs.

SOURCE NeuroSense